News - Astellas Pharma, Gastro-intestinals

Filter

Popular Filters

Astellas and UMN update on Ph III trials of flu vaccine ASP7374; debuts Irribow OD in Japan

Astellas and UMN update on Ph III trials of flu vaccine ASP7374; debuts Irribow OD in Japan

15-01-2014

Japanese drug major Astellas Pharma and partner UMN Pharma have announced promising summary results for…

Asia-PacificASP7374Astellas PharmaGastro-intestinalsIrribowMarkets & MarketingPharmaceuticalResearchUMN PharmaVaccines

Astellas gains marketing approval for Irribow

16-08-2013

Japanese drug major Astellas Pharma (TYO: 4503) has gained marketing approval in Japan for Irribow (ramosetron…

Asia-PacificAstellas PharmaGastro-intestinalsIrribowMarkets & MarketingPharmaceutical

Zeria and Astellas' Acofide approved in Japan for functional dyspepsia

27-03-2013

Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the marketing of Acofide (acotiamide…

AcofideAsia-PacificAstellas PharmaGastro-intestinalsPharmaceuticalRegulationZeria Pharmaceuticals

Astellas starts European roll-out of OAB drug Betmiga in UK

27-02-2013

The European subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) has started the European launch…

Astellas PharmaBetmigaEuropeGastro-intestinalsMarkets & MarketingPharmaceutical

Kyowa Hakko and Astellas get new indication for Pasetocin and Sawacillin; latter applies for new Dormicum use

21-02-2013

Japanese drug major Kyowa Hakko Kirin (TYO: 4151) and Astellas Pharma (TYO: 4503) have jointly announced…

Asia-PacificAstellas PharmaDormicumGastro-intestinalsKyowa Hakko KirinNeurologicalPasetocinPharmaceuticalRegulationSawacillin

Astellas and Drais partner to develop IBS compound through Seldar

05-06-2012

Japanese drug major Astellas Pharma (Tokyo: 4503) has entered into a second partnership in as many month…

ASP3291Astellas PharmaDrais PharmaceutialsFinancialGastro-intestinalsPharmaceuticalResearchSeldar Pharma

Astellas partners with Drais to develop its ulcerative colitis compound

01-05-2012

apanese drug major Astellas Pharma (TYO: 4503) has entered into a uniquely structured partnership with…

Astellas PharmaDrais PharmaceutialsGastro-intestinalsLicensingPharmaceuticalTelsar Pharma

Astellas files for OAB drug mirabegron in USA and Europe

01-09-2011

Japanese drug major Astellas Pharma (TYO: 4503) says it has submitted a New Drug Application and Market…

Astellas PharmaBetanisGastro-intestinalsmirabegronPharmaceuticalRegulation

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top